Total: $83.771M | ||||
Company (Symbol)# |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
AmountRaised (M) |
Investors; Placement Agents; Details (Date)@ |
BioTime Inc.(AMEX:BTX) |
Private placement of common stock | 1.8S |
$2 |
BioTime raised about $2M in a private placementof about 1.8M shares through Ladenburg Thalmann & Co. Inc. (8/13) |
Cepheid Inc.(CPHD) |
Private placement of common stock |
4S |
$10 |
Cepheid raised $10M net in a sale of common stock to certain investors (8/2) |
Corixa Corp. (CRXA) |
Private placement of common stock |
7.3S |
$45 |
Corixa raised about $45M in a private placement of 7.3M shares; the financing was led by InterWest Partners; other investors were BankAmerica Ventures, Hambrecht & Quist Capital Management LLC, KBL Healthcare Ventures, Oxford Bioscience Partners and Sutter Hill Ventures; the placement agent was Pacific Growth Equities Inc. (8/12) |
Interferon Sciences Inc. (OTC BB:IFSC) |
Private placement of convertible notes |
N/A |
$0.5 |
Interferon completed a private placement of $500,000 in convertible notes to accredited investors (8/14) |
Miravant Medical Technologies Inc. (OTC BB:MRVT) |
Private placement of common stock. |
5S |
$2.5 |
Miravant sold to unnamed private investors 5M unregistered shares of common stock for $2.5M at 50 cents per share (8/29) |
Nymox Pharmaceuticals Corp. (NYMX) |
Private placement of common stock |
N/A |
$0.763 |
Nymox raised $763,000 through private placements with existing shareholders (8/2) |
Ortec International Inc. (ORTC) |
Private placement of convertible preferred stock |
N/A |
$8.5 |
Ortec issued $8.5M of Series B convertible preferred stock (8/28) |
Palatin Technologies Inc. (AMEX:PTN) |
Private placement of common stock |
2.6S |
$4.2 |
Palatin raised $4.2M in the private placement; investors were SCOR Picking, Credit Suisse Equity Fund Global Biotech, Perceptive Life Sciences Fund, Albert Fried and Co. and Finedix BV (8/2) |
Peregrine Pharmaceuticals Inc. (PPHM) |
Private placement of common stock |
N/A |
$7.1 |
Peregrine raised $7.1M in two private placement arrangements with seven institutional investors (8/12) |
Peregrine Pharmaceuticals Inc. (PPHM) |
Private placement of common stock |
2.9S |
$1.9 |
Peregrine raised $1.9M through the sale of 2.9M shares to one institutional investor pursuant to a shelf registration (8/13) |
Pheromone Sciences Corp. (Canada; TSE:PHS) |
Private placement of common stock |
1.3U |
C$0.325 (US$0.208) |
Pheromone completed a private placement of 1.3M units for gross proceeds of US$208,442 (8/16) |
StemCells Inc. (STEM) |
Private placement of common stock |
1.03S |
$1.1 |
StemCells raised $1.1M through a private place-ment with an institutional investor (8/28) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
N/A = Not available, applicable or reported. | ||||
AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange | ||||
To read more on related topics, click on one of the words below.